- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07951398
Bacillus Clausii or Lactobacillus Rhamnosus GG Added to Dietary Management in Young Children With Functional Constipation: a Prospective Comparative Study (BC-LGG-FC)
Bacillus Clausii or Lactobacillus Rhamnosus GG Added to Dietary Management in Children Aged 12-48 Months With Functional Constipation: A Prospective, Open-Label, Three-Arm Comparative Study
This prospective study compared Bacillus clausii and Lactobacillus rhamnosus GG, each added to dietary management, with dietary management alone in children aged 12-48 months with functional constipation (Rome IV). Children assigned to probiotic treatment were randomly allocated to Bacillus clausii or Lactobacillus rhamnosus GG (2 × 10⁹ spores or CFU daily for two months); consecutive children receiving dietary management alone served as controls. Defecation frequency, stool consistency, painful defecation and abdominal distension were assessed at baseline and at months 1 and 2.
Studie Overzicht
Toestand
Conditie
Gedetailleerde beschrijving
This prospective, open-label, three-arm comparative study was conducted at the pediatric gastroenterology outpatient clinic of Gaziosmanpaşa Taksim Training and Research Hospital, Istanbul, Türkiye, between February 2020 and July 2021.
Allocation: Children assigned to probiotic treatment were randomly allocated in a 1:1 ratio to the Bacillus clausii (BC) or Lactobacillus rhamnosus GG (LGG) group according to a computer-generated randomization list. The control group consisted of consecutive eligible children who presented during the same period and received dietary management alone; this group was not part of the randomization. No placebo was used, and caregivers and investigators were aware of group assignment.
Interventions: Children in the BC group received an oral suspension containing 2 × 10⁹ Bacillus clausii spores per 5-mL vial (Enterogermina®, Sanofi S.p.A., Italy), one vial once daily. Children in the LGG group received oral drops containing 1 × 10⁹ CFU of Lactobacillus rhamnosus GG (ATCC 53103) per 6 drops (Maflor®, Mamsel İlaç San. ve Tic. A.Ş., Türkiye), 12 drops once daily (2 × 10⁹ CFU/day). Both probiotics were administered for two months. All children, including those in the control group, received an individualized, age- and weight-appropriate fiber-rich diet plan together with advice on age-appropriate fluid intake. No laxatives or other pharmacological treatments for constipation were given.
Assessments: Weekly defecation frequency (caregiver stool diary), stool consistency (modified Bristol Stool Form Scale for children), painful defecation and abdominal distension were recorded at baseline and at months 1 and 2. Adherence to the probiotic and dietary recommendations was assessed by caregiver report at each follow-up visit.
Outcomes: The primary outcomes were weekly defecation frequency and the presence of painful defecation at month 2. Secondary outcomes were weekly defecation frequency at month 1, stool consistency at months 1 and 2, painful defecation at month 1 and abdominal distension at months 1 and 2.
Studietype
Inschrijving (Werkelijk)
Fase
- Niet toepasbaar
Contacten en locaties
Studie Locaties
-
-
-
Istanbul, Turkije (Türkiye), 34295
- Department of Pediatrics, Faculty of Medicine, Biruni University
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Age 12 to 48 months
- Functional constipation according to the Rome IV criteria for infants and toddlers (criterion G7): at least two of the following for at least one month: two or fewer defecations per week; history of excessive stool retention; history of painful or hard bowel movements; history of large-diameter stools; presence of a large fecal mass in the rectum. In toilet-trained children, at least one episode per week of incontinence after the acquisition of toileting skills and a history of large-diameter stools that may obstruct the toilet were also considered.
- Written informed consent from a parent or legal guardian
Exclusion Criteria:
- Organic cause of constipation (Hirschsprung disease, anorectal malformation, hypothyroidism, celiac disease, or a spinal or neuromuscular disorder)
- Developmental delay
- Previous gastrointestinal surgery
- Use of probiotics, laxatives or antibiotics within the preceding 8 weeks
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Niet-gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Bacillus clausii + dietary management
Bacillus clausii oral suspension, 2 × 10⁹ spores (one 5-mL vial) once daily for 2 months, in addition to individualized dietary management. |
Oral suspension containing 2 × 10⁹ Bacillus clausii spores per 5-mL vial; one vial once daily for 2 months.
Andere namen:
Individualized fiber-rich diet plan appropriate for age and body weight, with advice on age-appropriate fluid intake. |
|
Experimenteel: Lactobacillus rhamnosus GG + dietary management
Lactobacillus rhamnosus GG oral drops, 2 × 10⁹ CFU (12 drops) once daily for 2 months, in addition to individualized dietary management. |
Individualized fiber-rich diet plan appropriate for age and body weight, with advice on age-appropriate fluid intake. Oral drops containing 1 × 10⁹ CFU of Lactobacillus rhamnosus GG (ATCC 53103) per 6 drops; 12 drops once daily (2 × 10⁹ CFU/day) for 2 months.
Andere namen:
|
|
Actieve vergelijker: Dietary management alone
Individualized dietary management without a probiotic. Consecutive eligible children presenting during the same period; not randomized. |
Individualized fiber-rich diet plan appropriate for age and body weight, with advice on age-appropriate fluid intake. |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Weekly defecation frequency
Tijdsspanne: 2 months after the start of treatment
|
Number of bowel movements per week, recorded from a stool diary kept by the caregiver. |
2 months after the start of treatment
|
|
Proportion of children with painful defecation
Tijdsspanne: 2 months after the start of treatment
|
Presence or absence of painful defecation, based on caregiver report at the follow-up visit |
2 months after the start of treatment
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Weekly defecation frequency
Tijdsspanne: 1 month after the start of treatment
|
Number of bowel movements per week, recorded from a stool diary kept by the caregiver. |
1 month after the start of treatment
|
|
Stool consistency (modified Bristol Stool Form Scale for children)
Tijdsspanne: 1 month and 2 months after the start of treatment
|
Caregiver-rated stool form using the modified Bristol Stool Form Scale for children; higher scores indicate softer stools. |
1 month and 2 months after the start of treatment
|
|
Proportion of children with painful defecation
Tijdsspanne: 1 month after the start of treatment
|
Presence or absence of painful defecation, based on caregiver report at the follow-up visit. |
1 month after the start of treatment
|
|
Proportion of children with abdominal distension
Tijdsspanne: 1 month and 2 months after the start of treatment
|
Presence or absence of abdominal distension, assessed at the follow-up visit. |
1 month and 2 months after the start of treatment
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Studie directeur: ABDULLAH SERT, Department of Pediatrics, Faculty of Medicine, Biruni University
Publicaties en nuttige links
Algemene publicaties
- Benninga MA, Faure C, Hyman PE, St James Roberts I, Schechter NL, Nurko S. Childhood Functional Gastrointestinal Disorders: Neonate/Toddler. Gastroenterology. 2016 Feb 15:S0016-5085(16)00182-7. doi: 10.1053/j.gastro.2016.02.016. Online ahead of print.
- Lane MM, Czyzewski DI, Chumpitazi BP, Shulman RJ. Reliability and validity of a modified Bristol Stool Form Scale for children. J Pediatr. 2011 Sep;159(3):437-441.e1. doi: 10.1016/j.jpeds.2011.03.002. Epub 2011 Apr 13.
- Lojanatorn P, Phrommas J, Tanpowpong P, Getsuwan S, Lertudomphonwanit C, Treepongkaruna S. Efficacy of Bacillus clausii in Pediatric Functional Constipation: A Pilot of a Randomized, Double-Blind, Placebo-Controlled Trial. Indian Pediatr. 2023 Jun 15;60(6):453-458. Epub 2023 Feb 9.
- Gordon M, de Geus A, Boruta M, Banasiuk M, Benninga M, Borrelli O, Darbari A, Dore-Stites D, Gould M, Hawa J, Jones K, Kilgore A, Mousa H, Nurko S, Thapar N, Khlevner J, Sinopoulou V, Tabbers M. European Society for Paediatric Gastroenterology, Hepatology and Nutrition/North American Society for Pediatric Gastroenterology, Hepatology and Nutrition guidelines for treatment of functional constipation in children aged 0-18 years. J Pediatr Gastroenterol Nutr. 2026 Aug;83(2):335-366. doi: 10.1002/jpn3.70447. Epub 2026 May 20.
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- KAEK-151-2019
- Ethics decision 151/2019 (Andere identificatie: Taksim Training and Research Hospital Clinical Research Ethics Committee)
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
De-identified individual participant data underlying the reported results will be available from the corresponding author upon reasonable request.
IPD-tijdsbestek voor delen
Beginning after publication of the article, with no planned end date.
IPD-toegangscriteria voor delen
De-identified individual participant data underlying the reported results will be available to researchers who provide a methodologically sound proposal. Requests should be directed to the corresponding author (asert@biruni.edu.tr); data will be shared after approval of the request and a data-sharing agreement.
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
product vervaardigd in en geëxporteerd uit de V.S.
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .